10/23
07:08 am
gnta
Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" [Financial Post (Toronto, Ontario, Canada)]
10/23
07:00 am
gnta
Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
Medium
Report
Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
10/11
07:56 am
gnta
Genenta Science S.p.A.'s (NASDAQ:GNTA) market cap rose US$46m last week; individual investors who hold 55% profited and so did insiders [Yahoo! Finance]
High
Report
Genenta Science S.p.A.'s (NASDAQ:GNTA) market cap rose US$46m last week; individual investors who hold 55% profited and so did insiders [Yahoo! Finance]
10/2
11:20 am
gnta
Genenta Science S.p.A. (NASDAQ: GNTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Medium
Report
Genenta Science S.p.A. (NASDAQ: GNTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
10/2
06:36 am
gnta
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer [Financial Post (Toronto, Ontario, Canada)]
10/2
06:30 am
gnta
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Medium
Report
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer